Provided by Tiger Fintech (Singapore) Pte. Ltd.

Clearside Biomedical

0.7932
-0.0149-1.84%
Volume:25.10K
Turnover:20.02K
Market Cap:61.64M
PE:-1.95
High:0.8050
Open:0.8050
Low:0.7900
Close:0.8081
Loading ...

Director Makes Bold Move with New Stock Purchase in Clearside Biomedical

TIPRANKS
·
25 Feb

Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?

Zacks
·
24 Feb

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of Its New Drug Application for Arcatus® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

THOMSON REUTERS
·
20 Feb

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

GlobeNewswire
·
20 Feb

JonesResearch sees buying opportunity in Clearside ahead of 2025 updates

TIPRANKS
·
12 Feb

Clearside Biomedical Announces Additional Data From the Cls-Ax Odyssey Phase 2B Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

THOMSON REUTERS
·
10 Feb

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

GlobeNewswire
·
10 Feb

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

GlobeNewswire
·
04 Feb

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

GlobeNewswire
·
28 Jan

Clearside's Partner Receives NDA Approvals for Uveitic Macular Edema Treatment in Australia, Singapore

MT Newswires Live
·
23 Jan

Clearside Biomedical Announces Its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

THOMSON REUTERS
·
22 Jan

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

GlobeNewswire
·
22 Jan

Further weakness as Clearside Biomedical (NASDAQ:CLSD) drops 14% this week, taking five-year losses to 72%

Simply Wall St.
·
21 Dec 2024

Clearside announces publication of insights on drug development, regulation

TIPRANKS
·
19 Dec 2024

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

GlobeNewswire
·
19 Dec 2024

Clearside Biomedical Highlights Advancements in Drug Delivery

TIPRANKS
·
13 Dec 2024